Imfinzi approved in the EU for less-frequent, fixed- dose use in unresectable non-small cell lung cancer
New option extends dosing from two to four weeks, reducing medical visits and improving patient convenienceAstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union and the UK for an additional dosing option, a 1,500mg fixed dose every four weeks, in locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on at least 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy (CRT). Lung cancer is the leading cause of cancer death and 80-85% of patients with lung cancer have NSCLC.
